STUDI IN SILICO FITOKIMIA UMBI BAWANG DAYAK (Eleutherine bulbosa L.) SEBAGAI INHIBITOR KANKER PAYUDARA DENGAN TARGET POLY (ADP-RIBOSE) POLYMERASE-1 DAN UJI IN VITRO PADA LINI SEL KANKER PAYUDARA MCF-7

Fahrul Nurkolis, NIM.: 20106040012 (2024) STUDI IN SILICO FITOKIMIA UMBI BAWANG DAYAK (Eleutherine bulbosa L.) SEBAGAI INHIBITOR KANKER PAYUDARA DENGAN TARGET POLY (ADP-RIBOSE) POLYMERASE-1 DAN UJI IN VITRO PADA LINI SEL KANKER PAYUDARA MCF-7. Skripsi thesis, UIN SUNAN KALIJAGA YOGYAKARTA.

Preview	Text (STUDI IN SILICO FITOKIMIA UMBI BAWANG DAYAK (Eleutherine bulbosa L.) SEBAGAI INHIBITOR KANKER PAYUDARA DENGAN TARGET POLY (ADP-RIBOSE) POLYMERASE-1 DAN UJI IN VITRO PADA LINI SEL KANKER PAYUDARA MCF-7) 20106040012_BAB-I_IV-atau-V_DAFTAR-PUSTAKA.pdf - Published Version Download (2MB) | Preview
	Text (STUDI IN SILICO FITOKIMIA UMBI BAWANG DAYAK (Eleutherine bulbosa L.) SEBAGAI INHIBITOR KANKER PAYUDARA DENGAN TARGET POLY (ADP-RIBOSE) POLYMERASE-1 DAN UJI IN VITRO PADA LINI SEL KANKER PAYUDARA MCF-7) 20106040012_BAB-II_sampai_SEBELUM-BAB-TERAKHIR.pdf - Published Version Restricted to Registered users only Download (2MB) | Request a copy

Abstract

The discovery of new candidate compounds from natural sources to treat breast cancer is important for the development of functional foods and the pharmaceutical industry. One source of natural ingredients that has the potential to be a drug candidate for breast cancer is forest onion Eleutherine bulbosa Extract (EBE), however the identity of the compound and its mechanism are still unknown. Therefore, this study focuses on metabolite profiles, activity and mechanisms in silico or pharmacoinformatics as well as further validation in in vitro cell lines. In EBE, 10 potential compounds were observed as candidates for further in silico anti-breast cancer testing. Ten compounds identified in EBE showed anticancer and radical inhibition activities. The most promising compound is avenasterol which binds PARP-1, HER2, iNOS receptors with ΔG values of -11.26, -8.34, and -9.17. EBE was observed to have a smaller EC50 value or greater potential than the trolox control as an antioxidant, both through the ABTS and DPPH tests. In line with in silico studies, EBE showed antiproliferative activity in human breast cancer MCF-7 with an IC50 value of 217.8 μg/mL while it was relatively safe in normal MCF-10A cells (IC50>1,000 μg/mL). Based on this study, it can be concluded that the antiproliferative molecular mechanism of EBE in MCF-7 is associated with downregulation of PARP1, HER2, and iNOS which are known as tumor activators.

Share this knowledge with your friends :

Actions (login required)

View Item